BOSENTAN VIATRIS bosentan (as monohydrate) 125 mg film-coated tablet blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bosentan viatris bosentan (as monohydrate) 125 mg film-coated tablet blister pack

alphapharm pty ltd - bosentan monohydrate, quantity: 129.082 mg - tablet, film coated - excipient ingredients: povidone; glyceryl behenate; sodium lauryl sulfate; maize starch; sodium starch glycollate type a; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; purified talc; triacetin; purified water; strong ammonia solution; ethylcellulose; oleic acid; medium chain triglycerides - bosentan viatris is indicated for the treatment of,? idiopathic pulmonary arterial hypertension,? familial pulmonary arterial hypertension,? pulmonary arterial hypertension associated with scleroderma or,? pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger?s physiology ,in patients with who functional class ii, iii or iv symptoms

BOSENTAN CIPLA bosentan 125 mg (as monohydrate) tablet blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 125 mg (as monohydrate) tablet blister pack

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 125 mg (as monohydrate) tablet bottle Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 125 mg (as monohydrate) tablet bottle

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 62.5 mg (as monohydrate) tablet blister pack Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 62.5 mg (as monohydrate) tablet blister pack

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN CIPLA bosentan 62.5 mg (as monohydrate) tablet bottle Ástralía - enska - Department of Health (Therapeutic Goods Administration)

bosentan cipla bosentan 62.5 mg (as monohydrate) tablet bottle

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

BOSENTAN TEVA 125 MG Ísrael - enska - Ministry of Health

bosentan teva 125 mg

abic marketing ltd, israel - bosentan as monohydrate - film coated tablets - bosentan as monohydrate 125 mg - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.

BOSENTAN TEVA 62.5 MG Ísrael - enska - Ministry of Health

bosentan teva 62.5 mg

abic marketing ltd, israel - bosentan as monohydrate - film coated tablets - bosentan as monohydrate 62.5 mg - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease.

Bosentan Zentiva 125 mg film-coated tablets Írland - enska - HPRA (Health Products Regulatory Authority)

bosentan zentiva 125 mg film-coated tablets

zentiva k.s. - bosentan monohydrate - film-coated tablet - bosentan

Bosentan Zentiva 62.5 mg film-coated tablets Írland - enska - HPRA (Health Products Regulatory Authority)

bosentan zentiva 62.5 mg film-coated tablets

zentiva k.s. - bosentan monohydrate - film-coated tablet - bosentan

Bosentan Viatris Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

bosentan viatris

viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg;  ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.